BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 31128201)

  • 21. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
    Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
    Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
    Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
    Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
    Neubauer A
    Internist (Berl); 2017 Apr; 58(4):409-423. PubMed ID: 28303311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 and PD-L1 antibodies for melanoma.
    Tsai KK; Zarzoso I; Daud AI
    Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
    Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
    Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
    Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
    J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.
    Hu X; Que W; Hirano H; Wang Z; Nozawa N; Ishii T; Ishizuka M; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Guo WZ; Li XK
    Cancer Sci; 2021 Jul; 112(7):2652-2663. PubMed ID: 33934440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD103
    Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
    Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
    [No Abstract]   [Full Text] [Related]  

  • 37. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
    Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
    J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.